Tidal Investments’s Protagonist Therapeutics PTGX Stock Holding History

Tidal Investments’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$611K	Sell	4,988 -6,046	-55%	-$632K	﹤0.01%	1995
2026 Q1	$1.16M	Buy	+11,034	New	+$977K	﹤0.01%	1395
2025 Q4	–	Sell	-8,945	Closed	-$594K	–	2292
2025 Q3	$594K	Sell	8,945 -14,832	-62%	-$843K	﹤0.01%	1478
2025 Q2	$1.31M	Buy	23,777 +4,367	+22%	+$210K	0.01%	905
2025 Q1	$939K	Sell	19,410 -1,602	-8%	-$67.1K	0.01%	1000
2024 Q4	$811K	Sell	21,012 -1,050	-5%	-$45.8K	0.01%	1114
2024 Q3	$993K	Hold	22,062	–	–	0.01%	991
2024 Q2	$764K	Buy	+22,062	New	+$646K	0.01%	1041

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Tidal Investments's PTGX Position: Q2 2026 in Review

Tidal Investments reduced its Protagonist Therapeutics (PTGX) stake by 55% in Q2 2026, selling an estimated $632K and leaving 4,988 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #1995.

Tidal Investments first reported a position in PTGX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.31M in Q2 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Tidal Investments held 4,988 shares of Protagonist Therapeutics worth $611K as of Q2 2026.
Tidal Investments sold 6,046 Protagonist Therapeutics shares in Q2 2026, an estimated $632K.
Protagonist Therapeutics made up ﹤0.01% of Tidal Investments's portfolio in Q2 2026, its #1995 holding.
Tidal Investments first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 8 quarters since.
Tidal Investments's Protagonist Therapeutics position peaked at $1.31M in Q2 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Tidal Investments's 13F filing for Q2 2026, filed 13 Aug 2026.